GRI Bio (GRI Bio) Interest Coverage : N/A (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is GRI Bio Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. GRI Bio's Operating Income for the three months ended in Mar. 2024 was $-1.90 Mil. GRI Bio's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for GRI Bio's Interest Coverage or its related term are showing as below:

GRI's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

GRI Bio Interest Coverage Historical Data

The historical data trend for GRI Bio's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

GRI Bio Interest Coverage Chart

GRI Bio Annual Data

Trend

Dec21

Dec22

Dec23

Interest Coverage

GRI Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial					-	-	No Debt	No Debt	N/A

Competitive Comparison of GRI Bio's Interest Coverage

For the Biotechnology subindustry, GRI Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GRI Bio's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GRI Bio's Interest Coverage distribution charts can be found below:

* The bar in red indicates where GRI Bio's Interest Coverage falls into.

GRI Bio Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

GRI Bio's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, GRI Bio's Interest Expense was $-2.08 Mil. Its Operating Income was $-11.39 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

GRI Bio did not have earnings to cover the interest expense.

GRI Bio's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, GRI Bio's Interest Expense was $0.00 Mil. Its Operating Income was $-1.90 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.11 Mil.

GuruFocus does not calculate GRI Bio's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

GRI Bio (NAS:GRI) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

GRI Bio Interest Coverage Related Terms

Thank you for viewing the detailed overview of GRI Bio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

GRI Bio (GRI Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037

Website

https://www.gribio.com

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.

Executives

David Leslie Szekeres	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson	director	20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro	officer: Chief Medical Officer	828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz	director, 10 percent owner, officer: Chief Executive Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi	officer: Chief Scientific Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne	director	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly	officer: Chief Financial Officer	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell	director	1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc.	10 percent owner	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren	officer: SVP, Regul Affairs & Prog Mgmt	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi	director	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer	director, 10 percent owner	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon	10 percent owner	SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052